GIM-531, Anti-PD-1 monoclonal antibody — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12 (month) in 2mo
ESTIMATED |
READOUT
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Phase 1/2 · Melanoma Stage IV, Solid Tumor |
Georgiamune Inc | GIM-531, Anti-PD-1 monoclonal antibody |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|